Belle Review – “No BMI Restrictions” Is Not a Feature

Belle sells compounded semaglutide from $119 a month and compounded tirzepatide from $175, with dose increases, nutrition guidance and nurse support included. Those inclusions are better than most of this category offers. The problem is on the same page, presented as a selling point.

The “No BMI Restrictions” Problem

Those thresholds are how the drugs were studied and how they are approved. Removing them is not a convenience improvement — it is removing the clinical criterion that determines whether the risk-benefit balance favours treatment at all. Presenting that as a feature tells you the intake is built to qualify people rather than to assess them.

It matters most for the people it will attract. Someone at a healthy weight who wants to lose ten pounds is exactly who a no-threshold policy admits, and they are the group for whom GLP-1 risks — gastrointestinal effects, gallbladder disease, pancreatitis, muscle loss — are least justified by benefit. There is also a real overlap with disordered eating, covered in our Octave review: a service that never asks about BMI is unlikely to be screening for it either.

In fairness, the phrase may be aimed at people slightly under a threshold who have a genuine comorbidity and have been refused elsewhere — a real and frustrating situation. But that case is handled by assessing the comorbidity, not by announcing there is no threshold. Our eligibility guide covers where the lines actually sit.

Pricing and Inclusions

What is included is the genuinely good part: dose increases at no extra cost, nutrition guidance, nurse support, questions answered within 24 hours, and 3 to 5 day delivery. Dose escalation being free matters more than it sounds — a headline price quoted at a starting dose that rises as you titrate is one of the most common ways these programmes get expensive, and Belle appears to have closed it.

It states no insurance is required and that treatments are FSA/HSA eligible. The compounded status carries the standing caveat: the shortage pathway that permitted mass compounding closed when the FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage on 21 February 2025 — see our compounded versus brand-name guide.

The Longevity Add-Ons

Alongside the GLP-1s, Belle sells NAD+ from $149 a month, microdose tirzepatide, MIC+B12, sermorelin and glutathione. This is the same stack we assessed in our System Labs review, and the same objections apply.

MIC+B12 lipotropic injections have essentially no controlled evidence of producing weight loss, and B12 helps only if you are deficient — which a blood test establishes for less than a month of injections. NAD+ and glutathione have thin human evidence for the benefits implied.

Microdose tirzepatide deserves its own note, because it sounds clinical and is not. There is no established microdosing protocol for tirzepatide; the drug was studied at specific escalating doses, and a sub-therapeutic dose is not a validated regimen with a smaller side-effect profile — it is an unstudied dose. If it is being offered to people who do not meet treatment criteria, the two problems on this page compound each other.

Provider Facts

Pros and Cons

Who It May Be Best For

Potentially suitable if you clearly meet standard treatment criteria, you want free dose escalation and bundled support, and you have decided on compounded medication with the regulatory position understood.

Not suitable if you are drawn here specifically because you do not meet the BMI criteria elsewhere. That is the situation the criteria exist for, and a service advertising their absence is not the one to resolve it.

Skip the add-ons. If you want the GLP-1, buy the GLP-1.

Alternatives

Zappy Health offers brand-name Wegovy pills from $149 — approved product, comparable price. Our cheapest GLP-1 programs page ranks by published price with membership fees flagged, and best compounded GLP-1 providers covers the compounded field specifically.

Limitations of This Review

Based on Belle’s published pages checked on 8 August 2026. Prices are “from” figures as displayed; we did not complete an intake and cannot confirm what patients are charged in practice. We could not establish states served, lab requirements, the name of the compounding pharmacy, prescriber credentials or visit cadence, or cancellation and refund terms, and we found no independent review record. The BMI criteria described are standard prescribing thresholds from published guidance, not Belle’s own statements. Nothing here is medical advice.

Frequently Asked Questions

Verdict

Free dose escalation and bundled nurse support are real advantages, and we would happily rate a service higher for them. But a programme that markets the absence of BMI criteria, then also offers microdose tirzepatide, is optimising for who it can sell to rather than who should be treated.